Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab deruxtecan + durvalumab + paclitaxel
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This combination comprises three agents: **trastuzumab deruxtecan**, an antibody-drug conjugate (ADC) that targets HER2 and delivers a topoisomerase I inhibitor payload; **durvalumab**, a monoclonal antibody checkpoint inhibitor that blocks PD-L1, enhancing antitumor immune response; and **paclitaxel**, a cytotoxic chemotherapy agent that interferes with microtubule function to inhibit cancer cell division. The regimen is under clinical investigation for the treatment of metastatic breast cancer (both HER2-positive and HER2-low subtypes), leveraging targeted therapy, immune modulation, and cytotoxic therapy[1][3][9].
- Brand names
- Enhertu (trastuzumab deruxtecan)Imfinzi (durvalumab)Taxol (paclitaxel)
- Other names
- T-DXd + durvalumab + paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))CD274 (Programmed cell death protein 1 ligand 1)TOP1 (DNA Topoisomerase I)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on trastuzumab deruxtecan + durvalumab + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab deruxtecan + durvalumab + paclitaxel.